抗真菌治療薬市場は174億ドルに達すると予想され、世界的な真菌感染症の発生の増加により、メーカーはより良い臨床転帰を目指して強化された製剤の開発を推進しているため、3.3%のCAGRで成長する見込みです。これにより、予測期間全体を通じて市場の拡大が促進されます。その結果、メーカーはナノテクノロジーを利用して製造できる新しい医薬品製剤に注目しています。
目次
Table of Content
Table of Content
1. Executive Summary
1.1. Regional Market Share
1.2. Business Trends
1.3. Anti-Fungal Treatment Market: COVID-19 Outbreak
1.4. Regional Trends
1.5. Segmentation Snapshot
2. Research Methodology
2.1. Research Objective
2.2. Research Approach
2.3. Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1. Paid Sources
2.5.2. Public Sources
2.6. Market Size Estimation and Data Triangulation
3. Market Characteristics
3.1. Market Definition
3.2. Anti-Fungal Treatment Market: COVID-19 Impact
3.3. Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data
4. Anti-Fungal Treatment Market - Industry Insights
4.1. Industry Segmentation
4.2. COVID-19 overview on world economy
4.3. Industry ecosystem Channel analysis
4.4. Innovation & Sustainability
5. Macroeconomic Indicators
6. Recent Developments
7. Market Dynamics
7.1. Introduction
7.2. Growth Drivers
7.3. Market Opportunities
7.4. Market Restraints
7.5. Market Trends
8. Risk Analysis
9. Market Analysis
9.1. Porters Five Forces
9.2. PEST Analysis
9.2.1. Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10. Anti-Fungal Treatment Market
10.1. Overview
10.2. Historical Analysis (2019-2021)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11. Anti-Fungal Treatment Market Size & Forecast 2022A-2032F
11.1. Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1. By Drug Type
11.3.1.1. Echinocandins
11.3.1.1.1. By Value (USD Million) 2022-2032F
11.3.1.1.2. Market Share (%) 2022-2032F
11.3.1.1.3. Y-o-Y Growth (%) 2022-2032F
11.3.1.2. Azoles
11.3.1.2.1. By Value (USD Million) 2022-2032F
11.3.1.2.2. Market Share (%) 2022-2032F
11.3.1.2.3. Y-o-Y Growth (%) 2022-2032F
11.3.1.3. Polyenes
11.3.1.3.1. By Value (USD Million) 2022-2032F
11.3.1.3.2. Market Share (%) 2022-2032F
11.3.1.3.3. Y-o-Y Growth (%) 2022-2032F
11.3.1.4. Allylamines
11.3.1.4.1. By Value (USD Million) 2022-2032F
11.3.1.4.2. Market Share (%) 2022-2032F
11.3.1.4.3. Y-o-Y Growth (%) 2022-2032F
11.3.2. By Indication
11.3.2.1. Dermatophytosis
11.3.2.1.1. By Value (USD Million) 2022-2032F
11.3.2.1.2. Market Share (%) 2022-2032F
11.3.2.1.3. Y-o-Y Growth (%) 2022-2032F
11.3.2.2. Aspergillosis
11.3.2.2.1. By Value (USD Million) 2022-2032F
11.3.2.2.2. Market Share (%) 2022-2032F
11.3.2.2.3. Y-o-Y Growth (%) 2022-2032F
11.3.2.3. Candidiasis
11.3.2.3.1. By Value (USD Million) 2022-2032F
11.3.2.3.2. Market Share (%) 2022-2032F
11.3.2.3.3. Y-o-Y Growth (%) 2022-2032F
11.3.2.4. Others
11.3.2.4.1. By Value (USD Million) 2022-2032F
11.3.2.4.2. Market Share (%) 2022-2032F
11.3.2.4.3. Y-o-Y Growth (%) 2022-2032F
11.3.3. By Route of Administration
11.3.3.1 Oral
11.3.3.1.1By Value (USD Million) 2022-2032F
11.3.3.1.2 Market Share (%) 2022-2032F
11.3.3.1.3 Y-o-Y Growth (%) 2022-2032F
11.3.3.2Topical
11.3.3.2.1 By Value (USD Million) 2022-2032F
11.3.3.2.2Market Share (%) 2022-2032F
11.3.3.3.1 Y-o-Y Growth (%) 2022-2032F
11.3.3.3Parenteral
11.3.3.3.1 By Value (USD Million) 2022-2032F
11.3.4.1.2 Market Share (%) 2022-2032F
11.3.4.1.3 Y-o-Y Growth (%) 2022-2032F
11.3.4 By Distribution Channel
11.3.4.1 Hospital Pharmacies
11.3.4.1.1By Value (USD Million) 2022-2032F
11.3.4.1.2 Market Share (%) 2022-2032F
11.3.4.1.3 Y-o-Y Growth (%) 2022-2032F
11.3.4.2Retail Pharmacies & Drug Store
11.3.4.2.1 By Value (USD Million) 2022-2032F
11.3.4.2.2Market Share (%) 2022-2032F
11.3.4.2.3Y-o-Y Growth (%) 2022-2032F
11.3.4.3Others
11.3.4.3.1 By Value (USD Million) 2022-2032F
11.3.4.3.2Market Share (%) 2022-2032F
11.3.4.3.3Y-o-Y Growth (%) 2022-2032F
12. North America Anti-Fungal Treatment Market Size & Forecast 2022A-2032F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Drug Type
12.3.2. By Indication
12.3.3. By Route of Administration
12.3.4. By Distribution Channel
12.4. Country
12.4.1. United States
12.4.2. Canada
13. Europe Anti-Fungal Treatment Market Size & Forecast 2022A-2032F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. By Drug Type
13.3.2. By Indication
13.3.3. By Route of Administration
13.3.4. By Distribution Channel
13.4. Country
13.4.1. Germany
13.4.2. United Kingdom
13.4.3. France
13.4.4. Italy
13.4.5. Spain
13.4.6. Russia
13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14. Asia-Pacific Anti-Fungal Treatment Market Size & Forecast 2022A-2032F
14.1. Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Drug Type
14.3.2. By Indication
14.3.3. By Route of Administration
14.3.4. By Distribution Channel
14.4. Country
14.4.1. India
14.4.2. China
14.4.3. South Korea
14.4.4. Japan
14.4.5. Rest of APAC
15. Middle East and Africa Anti-Fungal Treatment Market Size & Forecast 2022A-2032F
15.1. Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Drug Type
15.3.2. By Indication
15.3.3. By Route of Administration
15.3.4. By Distribution Channel
15.4. Country
15.4.1. Israel
15.4.2. GCC
15.4.3. North Africa
15.4.4. South Africa
15.4.5. Rest of Middle East and Africa
16. Latin America Anti-Fungal Treatment Market Size & Forecast 2022A-2032F
16.1. Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1. By Drug Type
16.3.2. By Indication
16.3.3. By Route of Administration
16.3.4. By Distribution Channel
16.4. Country
16.4.1. Mexico
16.4.2. Brazil
16.4.3. Rest of Latin America
17. Competitive Landscape
17.1. Company market share, 2021
17.2. Key player overview
17.3. Key stakeholders
18. Company Profiles
18.1. Pfizer Inc.
18.1.1. Company Overview
18.1.2. Financial Overview
18.1.3. Key Product; Analysis
18.1.4. Company Assessment
18.1.4.1. Product Portfolio
18.1.4.2. Key Clients
18.1.4.3. Market Share
18.1.4.4. Recent News & Development (Last 3 Yrs.)
18.1.4.5. Executive Team
18.2. Novartis AG
18.3. Gilead Sciences, Inc.
18.4. Merck & Co., Inc.
18.5. Johnson & Johnson
18.6. Astellas Pharma Inc.
18.7. GlaxoSmithKline plc.
18.8. AbbVie Inc.
18.9. Eli Lilly and Company
18.10. Bristol-Myers Squibb Company
18.11. Sanofi S. A.
18.12. Bayer AG
18.13. Teva Pharmaceutical Industries Ltd.
18.14. Mylan N. V.
18.15. Basilea Pharmaceutica AG
18.16. Other Prominent Players
19. Appendix
20. Consultant Recommendation